Prognostic factors in low-grade non-Hodgkin lymphomas

[1]  Giovanni Martinelli,et al.  Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Crowley,et al.  International prognostic scoring system for Waldenstrom macroglobulinemia. , 2009, Blood.

[3]  J. Friedberg,et al.  Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. , 2009, Blood.

[4]  L. Staudt,et al.  Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. , 2009, Blood.

[5]  L. Staudt,et al.  The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. , 2008, Blood.

[6]  Sonia Jain,et al.  Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. , 2008, Blood.

[7]  Emili Montserrat,et al.  New prognostic markers in chronic lymphocytic leukemia. , 2008, Blood reviews.

[8]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[9]  M. Karjalainen‐Lindsberg,et al.  Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP. , 2008, Blood.

[10]  A. Levis,et al.  Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. , 2008, Blood.

[11]  G. Salles,et al.  High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Tilly,et al.  Epidemiology, pathology and treatment of non-follicular indolent lymphomas , 2008, Leukemia & lymphoma.

[13]  M. Federico,et al.  Incidence, clinical characteristics and survival of malignant lymphomas: a population‐based study from a cancer registry in northern Italy , 2007, Hematological oncology.

[14]  K. Do,et al.  Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Karjalainen‐Lindsberg,et al.  A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone , 2007, Clinical Cancer Research.

[16]  Carsten Schrader,et al.  Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T Hamblin,et al.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2007, The Lancet.

[18]  Kim-Anh Do,et al.  Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. , 2007, Blood.

[19]  F. Angrilli,et al.  Introduction of rituximab in front‐line and salvage therapies has improved outcome of advanced‐stage follicular lymphoma patients , 2007, Cancer.

[20]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Raemaekers,et al.  The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma. , 2007, Haematologica.

[22]  Marylène Lejeune,et al.  Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Max Wolf,et al.  Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. , 2006, Blood.

[24]  E. Hoster,et al.  The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect , 2006, Blood.

[25]  E. Iannitto,et al.  Splenic marginal zone lymphoma: a prognostic model for clinical use. , 2006, Blood.

[26]  B. Coiffier,et al.  Management of marginal zone lymphomas , 2006, Current treatment options in oncology.

[27]  M. Caligiuri,et al.  Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Stolte,et al.  Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Karey Shumansky,et al.  Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). , 2005, Blood.

[30]  Christian Buske,et al.  Treatment strategies in follicular lymphomas: current status and future perspectives. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  R. Marcus,et al.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.

[32]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[33]  A. López-Guillermo,et al.  Follicular lymphoma international prognostic index. , 2004, Blood.

[34]  Emili Montserrat,et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.

[35]  A. López-Guillermo,et al.  Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. , 2003, Blood.

[36]  R. Gascoyne,et al.  Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes , 2003, British journal of haematology.

[37]  E. Haralambieva,et al.  Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. , 2003, Blood.

[38]  D. Oscier,et al.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. , 2002, Blood.

[39]  B. Cheson.  Chronic Lymphoid Leukemias , 2001 .

[40]  C. Copie-Bergman,et al.  Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome , 2001, American Journal of Gastroenterology.

[41]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[42]  B. Grosbois,et al.  patients with the description of a new scoring system and its validation on 253 other patients. , 2000, Blood.

[43]  G. Salles,et al.  Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. , 2000, Blood.

[44]  T. Chisesi,et al.  Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi. , 2000, Blood.

[45]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[46]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[47]  B. Nathwani,et al.  Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[49]  Annick,et al.  Prognostic value of chromosomal abnormalities in follicular lymphoma. , 1994, Blood.

[50]  S. Molica.  Progression and survival studies in early chronic lymphocytic leukemia. , 1991, Blood.

[51]  S. Horning,et al.  Small lymphocytic lymphoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  E. Montserrat,et al.  Prognostic factors in chronic lymphocytic leukemia. , 1987, Seminars in hematology.

[53]  O. Kucuk,et al.  Effect of the degree of nodularity on the survival of patients with nodular lymphomas. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Mark J. Thomas,et al.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.

[55]  E. Cronkite,et al.  Clinical staging of chronic lymphocytic leukemia. , 1975, Blood.

[56]  Henry Rappaport,et al.  Follicular lymphoma. A re‐evaluation of its position in the scheme of malignant lymphoma based on a survey of 253 cases , 1956 .

[57]  C. Pascutto,et al.  Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[58]  Juan F. García,et al.  The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. , 2006, Haematologica.

[59]  Peter Joosten,et al.  Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. , 2005, Blood.

[60]  A. López-Guillermo,et al.  Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.